GlaxoSmithKline Abreva $10 Mil. Sales Help Offset Smoking Cessation Woes
This article was originally published in The Tan Sheet
Executive Summary
GlaxoSmithKline's Abreva posted $10 mil. in sales during the OTC cold sore medication's first full quarter on the U.S. market.
You may also be interested in...
Block Boosts GSK Consumer Group In Q2, Offsets NicoDerm, Nicorette Losses
GlaxoSmithKline's consumer healthcare sales rose 19% to $1.15 bil. in the second quarter due to the addition of Block Drug's OTC portfolio. Excluding Block revenue, sales declined 2%, largely reflecting the firm's faltering smoking cessation business.
Block Boosts GSK Consumer Group In Q2, Offsets NicoDerm, Nicorette Losses
GlaxoSmithKline's consumer healthcare sales rose 19% to $1.15 bil. in the second quarter due to the addition of Block Drug's OTC portfolio. Excluding Block revenue, sales declined 2%, largely reflecting the firm's faltering smoking cessation business.
Block Boosts GSK Consumer Group In Q2, Offsets NicoDerm, Nicorette Losses
GlaxoSmithKline's consumer healthcare sales rose 19% to $1.15 bil. in the second quarter due to the addition of Block Drug's OTC portfolio. Excluding Block revenue, sales declined 2%, largely reflecting the firm's faltering smoking cessation business.